About 83% of breast cancer patients in the U.S. have hormone receptor (HR)-positive (i.e., estrogen and/or progesterone receptor-positive) tumors and are eligible for endocrine therapy (ET) [1]. The gene discussed is NR4A1; the disease is breast cancer.